Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus.

Philis-Tsimikas, A.; Astamirova, K.; Gupta, Y.; Haggag, A.; Roula, D.; Bak, B.; Fita, E.; Nielsen, A.; Demir, TEVFİK

doi:10.1016/j.diabres.2018.10.024

Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus.

Philis-Tsimikas A., Astamirova K., Gupta Y., Haggag A., Roula D., Bak B. A., ...Daha Fazla

Diabetes research and clinical practice, cilt.147, ss.157-165, 2019 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 147
Basım Tarihi: 2019
Doi Numarası: 10.1016/j.diabres.2018.10.024
Dergi Adı: Diabetes research and clinical practice
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.157-165
Anahtar Kelimeler: IDegAsp, Glargine, Aspart, Diabetes, Co-formulation, Hypoglycaemia
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Aims: To confirm non-inferiority of insulin degludec/insulin aspart (IDegAsp) once-daily (OD) versus insulin glargine (IGlar) U100 OD + insulin aspart (IAsp) OD for HbA(1c) after 26 weeks, and compare efficacy and safety between groups at W26 + W38.